Neogenomics (NEO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.05
- EPS estimate
- $0.03
- EPS surprise
- +49.25%
- Revenue surprise
- +2.40%
- Revenue
- $201.7M
- Revenue estimate
- $196.9M
- Reported
- Jul 28, 2026
NeoGenomics reported Q2 2026 results on July 28, 2026. Earnings per share were $0.05, ahead of the $0.03 estimate by 49.25%. Revenue of $201.7 million beat the $196.9 million consensus by 2.40% and was the first quarter above $200 million in the table. Compared with Q2 2025, EPS rose from $0.03 and revenue rose about 11% from $181.3 million.
Annual EPS was a loss of $0.56 per share in 2022 and of $0.11 in 2023, then a profit of $0.10 in 2024 and $0.12 in 2025. The last loss in the table was Q1 2024, at $0.02 per share. Revenue rose every year, from $509.8 million in 2022 to $727.3 million in 2025, up about 43%. The first half of 2026 adds up to $0.06 per share on $388.4 million in revenue, against $0.03 on $349.3 million a year earlier. NeoGenomics' surprise was positive in all 20 quarters shown.
Q3 results came out between October 28 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report, which will show whether revenue stays above $200 million.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 28, 2026 | $0.03 | $0.05 | +49.25% | $201.7M | SEC |
| Q1 2026 | Apr 28, 2026 | $0.01 | $0.01 | +72.41% | $186.7M | SEC |
| Q4 2025 | Feb 17, 2026 | $0.04 | $0.06 | +47.78% | $190.2M | SEC |
| Q3 2025 | Oct 28, 2025 | $0.02 | $0.03 | +46.34% | $187.8M | SEC |
| Q2 2025 | Jul 29, 2025 | $0.02 | $0.03 | +29.31% | $181.3M | SEC |
| Q1 2025 | Apr 29, 2025 | −$0.01 | $0.00 | +100.00% | $168.0M | SEC |
| Q4 2024 | Feb 18, 2025 | $0.03 | $0.04 | +38.89% | $172.0M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.01 | $0.05 | +306.50% | $167.8M | SEC |
| Q2 2024 | Jul 29, 2024 | −$0.00 | $0.03 | +1067.74% | $164.5M | SEC |
| Q1 2024 | Apr 30, 2024 | −$0.04 | −$0.02 | +49.62% | $156.2M | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.02 | $0.03 | +221.46% | $155.6M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.07 | $0.00 | +100.00% | $152.0M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.11 | −$0.05 | +56.18% | $146.9M | SEC |
| Q1 2023 | May 8, 2023 | −$0.14 | −$0.09 | +35.44% | $137.2M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.16 | −$0.06 | +63.55% | $138.7M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.21 | −$0.14 | +32.10% | $128.8M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.23 | −$0.16 | +31.77% | $125.1M | SEC |
| Q1 2022 | Apr 27, 2022 | −$0.24 | −$0.20 | +15.82% | $117.2M | SEC |
| Q4 2021 | Feb 23, 2022 | −$0.15 | −$0.14 | +7.22% | $125.7M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.09 | −$0.08 | +11.11% | $121.3M | SEC |
Quarterly revenue
Frequently asked questions
When did Neogenomics (NEO) last report earnings?
Neogenomics last reported on Jul 28, 2026, covering fiscal Q2 2026.
Did NEO beat earnings estimates?
Yes. Neogenomics reported EPS of $0.05 for Q2 2026 against a $0.03 estimate — a 49.25% beat.
How much revenue did NEO report last quarter?
Neogenomics reported $201.7M in revenue for Q2 2026, against a consensus estimate of $196.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.